Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sangamo Therapeutics Q3 EPS $(0.11) Misses $(0.01) Estimate, Sales $581.000K Miss $34.400M Estimate

Author: Benzinga Newsdesk | November 06, 2025 08:02am
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.01) by 1275 percent. This is a 375 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $581.000 thousand which missed the analyst consensus estimate of $34.400 million by 98.31 percent. This is a 98.82 percent decrease over sales of $49.412 million the same period last year.

Posted In: SGMO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist